Product Description
Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FR?)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent, to kill the targeted cancer cells.
Mechanisms of Action: FR1 Antagonist,Tubulin Antagonist
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: Accelerated Approval - Ovarian CancerPriority Review - Ovarian Cancer *
Approval Status: Approved
Approved Countries: Greece | United States
Approved Indications: None
Known Adverse Events: None
Company: ImmunoGen
Company Location: WALTHAM MA 02451
Company CEO: Mark Enyedy
Additonal Commercial Interests: Takeda
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Ireland, Israel, Italy, Japan, Korea, Netherlands, Norway, Philippines, Poland, Portugal, Russia, Serbia, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 23
Highest Development Phases
Phase 3: Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer
Phase 2: Endometrial Cancer
Phase 1: Carcinosarcoma|Mixed Tumor, Mullerian|Serous Cystadenocarcinoma|Uterine Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2011240046 | P3 |
Recruiting |
Peritoneal Cancer|Fallopian Tube Cancer|Ovarian Cancer |
2029-04-01 |
|
| IMGN853-0425 | P3 |
Not yet recruiting |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
2028-03-28 |
|
| IMNG853-0424 | P2 |
Unknown Status |
Ovarian Cancer |
2027-05-25 |
|
| GLORIOSA | P3 |
Recruiting |
Peritoneal Cancer|Fallopian Tube Cancer|Ovarian Cancer |
2027-03-01 |